# Effect of Remote Ischemic Preconditioning on the Incidence of Contrast Induced Nephropathy in Patients Undergoing EVAR

Study · id `cardio:ct-nct05350683` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05350683](<https://clinicaltrials.gov/study/NCT05350683>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05350683

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

## Technical summary

Registry record NCT05350683. Randomized; single masking; primary purpose prevention. Start 2017-01-01 (actual); primary completion 2019-09-17 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 120 participants (enrolled count; ClinicalTrials.gov record NCT05350683, source copy `cardio:ctgov-nct05350683-2022-04-28`, retrieved 2026-11-18)
- Started: 2017-01-01 (actual) (ClinicalTrials.gov record NCT05350683, source copy `cardio:ctgov-nct05350683-2022-04-28`, retrieved 2026-11-18)
- Primary completion: 2019-09-17 (actual) (ClinicalTrials.gov record NCT05350683, source copy `cardio:ctgov-nct05350683-2022-04-28`, retrieved 2026-11-18)
- Completion: 2020-05-20 (actual) (ClinicalTrials.gov record NCT05350683, source copy `cardio:ctgov-nct05350683-2022-04-28`, retrieved 2026-11-18)
- Countries: Spain (ClinicalTrials.gov record NCT05350683, source copy `cardio:ctgov-nct05350683-2022-04-28`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05350683-2022-04-28`, retrieved 2026-11-18)

## The registry's words

- Brief title: Effect of Remote Ischemic Preconditioning on the Incidence of Contrast Induced Nephropathy in Patients Undergoing EVAR
- Acronym: RIPC-EVAR
- Condition: Aortic Aneurysm
- Condition: Ischemic Preconditioning
- Intervention (Procedure): Remote ischemic preconditioning
- Lead sponsor: Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery
- Lead sponsor class: NETWORK
- Collaborator: Hospital Clínico Universitario de Valladolid
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic aneurysm (`cardio:aortic-aneurysm`)

## Provenance

Content hash: 67054f08a02f6cd4a51600cbcb081e28216fea7e856dba4c0ea28b7763650d47
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
